



About Amgen

Amgen discovers, develops, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing novel medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a broad and deep pipeline of potential new medicines, Amgen is committed to advancing science to dramatically improve people's lives.

Reaching Patients Worldwide

Amgen medicines help patients around the world. The company has facilities or subsidiaries in the following locations:

United States (including Puerto Rico)

- California (Fremont, South San Francisco, Thousand Oaks)
- Colorado (Boulder, Longmont)
- Kentucky (Louisville)
- Massachusetts (Cambridge)
- Puerto Rico (Juncos)
- Rhode Island (West Greenwich)
- Washington (Bothell, Seattle)
- Washington, D.C.

Outside the United States

Australia	Finland	Japan	Romania
Austria	France	Latvia	Russia
Belgium	Germany	Lithuania	Slovakia
Brazil	Greece	Luxembourg	Slovenia
Bulgaria	Hong Kong	Mexico	Spain
Canada	Hungary	The Netherlands	Sweden
Czech Republic	India	Norway	Switzerland
Denmark	Ireland	Poland	United Arab Emirates
Estonia	Italy	Portugal	United Kingdom

AMGEN MISSION

To serve patients

AMGEN QUICK FACTS

Headquarters

Thousand Oaks, California

Staff

Approximately 17,000 worldwide

Stock Listing

NASDAQ: AMGN

Chairman and CEO

Kevin W. Sharer

2009 Financial Highlights

Total revenue: \$14.6 billion
 Product sales: \$14.4 billion
 R&D expense: \$2.9 billion

Address/Phone

One Amgen Center Drive
 Thousand Oaks, CA 91320-1799

Main: (805) 447-1000

Investors: (805) 447-1060

PRINCIPAL PRODUCTS

- Aranesp® (darbepoetin alfa)
- Enbrel® (etanercept)
- EPOGEN® (Epoetin alfa)
- Neulasta® (pegfilgrastim)
- NEUPOGEN® (Filgrastim)
- Nplate® (romiplostim)
- Prolia™ (denosumab)
- Sensipar® (cinacalcet)
- Vectibix® (panitumumab)

For product information, including important safety information, visit www.amgen.com.

EXECUTIVE MANAGEMENT

Kevin W. Sharer
Chairman of the Board and
Chief Executive Officer

Robert A. Bradway
President and Chief Operating Officer

David W. Beier
Senior Vice President,
Global Government and Corporate Affairs

Fabrizio Bonanni
Executive Vice President,
Operations

Thomas J. Flanagan
Senior Vice President and
Chief Information Officer

Michael A. Kelly
Acting Chief Financial Officer

Brian M. McNamee
Senior Vice President,
Human Resources

George J. Morrow
Executive Vice President

Roger M. Perlmutter
Executive Vice President,
Research and Development

Anna S. Richo
Senior Vice President and
Chief Compliance Officer

David J. Scott
Senior Vice President,
General Counsel and Secretary

INVESTOR INFORMATION

This fact sheet is a summary of more detailed disclosure that can be found in Amgen's filings with the U.S. Securities and Exchange Commission and its press releases. This fact sheet contains forward-looking statements that involve significant risks and uncertainties, discussion of which can be found in Amgen's most recent Forms 10-K, 10-Q, and 8-K and on www.amgen.com/investors. The information in this fact sheet is given as of the date below, and Amgen does not undertake any obligation to update any information in this document.

An Interdisciplinary Approach to R&D

For 30 years, Amgen has been a leading innovator in the identification, isolation, production and use of human proteins as therapeutic agents. We focus on pioneering treatments for serious illness. Our R&D organization has cultivated expertise in multiple treatment modalities—large-molecule proteins, small molecules, and antibodies—allowing us to choose the best target for attacking disease and to use the modality most likely to affect that target. Our research facilities are located in South San Francisco and Thousand Oaks, California; Cambridge, Massachusetts; Seattle, Washington; Burnaby, British Columbia, Canada; Regensburg, Germany; and São Paulo, Brazil.

A Pioneer in Biotechnology Manufacturing

Assuring that Amgen medicines rapidly, reliably, and safely reach patients is the charge of Amgen's manufacturing, process development, quality, and distribution teams. Manufacturing therapies based on proteins found in the human body is a complex and highly specialized activity. From process development and clinical manufacturing to full-scale therapeutic protein production, Amgen has built one of the industry's largest and most reliable operations. Amgen operates manufacturing facilities in California, Colorado, Rhode Island, Washington, and Puerto Rico.

Advancing Science through Strategic Partnerships

With more than 100 active collaborations, Amgen is well-suited to be a partner of choice in the human therapeutics business. With the capabilities and financial strength of a large company, Amgen can offer partners the resources to support a potential new medicine as it advances from lab to clinic to marketplace. At the same time, Amgen retains the agility and decisiveness of a smaller biotech, with an unwavering commitment to science and patients.

Philanthropy that Makes a Positive Difference

The causes Amgen supports, through the Amgen Foundation and other channels, reflect the company's efforts to elevate science, help patients, and improve lives.

The Amgen Foundation

Since its founding in 1991, the Amgen Foundation has contributed more than \$140 million to regional and national nonprofit groups that advance science education, improve quality of care and access for patients, and support vital community resources. The Foundation also matches Amgen staff member donations to eligible organizations.

Science Education

Amgen is inspiring and preparing the scientists of tomorrow through several signature science education programs, including Amgen Scholars, an eight-year, \$27.5 million program for college undergraduates; the Teach for America Amgen Fellows Program; the Amgen Bruce Wallace Biotechnology Lab Program; and the Amgen Award for Science Teaching Excellence.

Community Involvement

In the communities in which Amgen staff live and work, the company commits millions of dollars in charitable donations, and staff members devote thousands of hours of personal time, to programs and services that can make meaningful differences in people's lives.

